Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Julien Sage



Author of

  • +

    MTE 10 - Bridging the Gap between Genomics and Clinics (Sign Up Required) (ID 559)

    • Event: WCLC 2017
    • Type: Meet the Expert
    • Track: Chemotherapy/Targeted Therapy
    • Presentations: 1
    • +

      MTE 10.02 - Bridging the Gap between Genomics and Clinics (ID 8216)

      07:30 - 08:00  |  Presenting Author(s): Julien Sage

      • Abstract
      • Presentation
      • Slides

      Abstract:
      Small cell lung cancer (SCLC) is a neuroendocrine subtype of lung cancer characterized by a fast growth rate, extensive dissemination, and rapid resistance to chemotherapy. Survival rates are dismal and have not significantly improved in the past few decades. Sequencing the genomes of over 100 human SCLC demonstrates universal inactivation of p53 and RB and identified inactivating recurrent mutations in NOTCH family genes (1). Accordingly, we found that activation of Notch signaling in a pre-clinical SCLC mouse model dramatically reduces the number of tumors and extends the survival of the mutant mice (1). Thus, Notch plays a key tumor suppressive role in SCLC and strategies to re-activate Notch in SCLC tumors may be beneficial to patients. We will present recent work focusing on the possible role of Notch-negative and Notch-positive cells in SCLC tumors during cancer progression and in response to chemotherapy (2). We will discuss how these results may be translatable to the clinic. At the histological level, SCLC tumor cells are often viewed as homogeneous. Our new studies and previous studies (3) identify several levels of intra-tumor heterogeneity in SCLC, which may contribute significantly to SCLC aggressive nature and resistance to therapy. 1. George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524:47-53. 2. Lim JS, Ibaseta A, Fischer MM, et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature 2017;545:360-364. 3. Calbo J, van Montfort E, Proost N, et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 2011;19:244-256.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.07 - Immunology and Immunotherapy (ID 708)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Immunology and Immunotherapy
    • Presentations: 1
    • +

      P2.07-062b - DNA Damage Repair Targeting Upregulates PD-L1 Level and Potentiates the Effect of PD-L1 Blockade in Small Cell Lung Cancer (ID 9733)

      09:30 - 09:30  |  Author(s): Julien Sage

      • Abstract
      • Slides

      Abstract not provided

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.15 - SCLC/Neuroendocrine Tumors (ID 716)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: SCLC/Neuroendocrine Tumors
    • Presentations: 1
    • +

      P2.15-016a - Exploiting G2-M Cell Cycle Checkpoint Dependency in Small Cell Lung Cancer (SCLC) by Targeting Checkpoint Kinase 1 (CHK1) (ID 9680)

      09:30 - 09:30  |  Author(s): Julien Sage

      • Abstract

      Abstract not provided